Non-aspirin NSAID use and mortality of endometrial cancer. A nationwide cohort study
| Autor: | Freija Verdoodt, Cecilie Dyg Sperling, Gitte Lerche Aalborg, Christian Dehlendorff, Søren Friis, Susanne K. Kjaer |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Cohort Studies 03 medical and health sciences 0302 clinical medicine Internal medicine Epidemiology medicine Humans 030212 general & internal medicine Registries Aged Proportional Hazards Models Aged 80 and over Aspirin business.industry Proportional hazards model Endometrial cancer Hazard ratio Confounding Anti-Inflammatory Agents Non-Steroidal Middle Aged medicine.disease Confidence interval Endometrial Neoplasms Oncology 030220 oncology & carcinogenesis Female business medicine.drug Cohort study |
| Zdroj: | Cancer causescontrol : CCC. 32(5) |
| ISSN: | 1573-7225 |
| Popis: | Laboratory studies have shown anti-neoplastic properties of non-aspirin NSAID; however, no studies have examined the influence of non-aspirin NSAIDs as potential adjuvant cancer therapy in women with endometrial cancer. We therefore examined the association between post-diagnostic use of non-aspirin NSAIDs and endometrial cancer mortality in Denmark. We identified all women with a primary endometrial cancer diagnosis between 2000 and 2012, who were alive one year after the diagnosis. Information on drug use, cause-specific mortality and potential confounders was obtained from nationwide health- and demographic registries. Cox regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnostic non-aspirin NSAID use and endometrial cancer mortality. Among 6 694 endometrial cancer patients with a maximum follow-up of 13 years, 753 women died from endometrial cancer. Post-diagnostic non-aspirin NSAID use (≥ 1 filled prescription) was associated with an overall HR of 1.15 (95% CI; 0.97–1.36) for endometrial cancer mortality, with higher HRs for the highest intensity of use (HR; 1.40, 95% CI; 1.11–1.77) and largest cumulative amount (HR; 1.56, 95% CI; 1.14–2.14). Our findings yielded no evidence that use of non-aspirin NSAIDs was associated with reduced endometrial cancer. Rather, we observed that high-intensity and large cumulative amount of non-aspirin NSAID use may be associated with increased endometrial cancer mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink